Upcoming Dividend • Mar 24
Upcoming dividend of CHF2.50 per share Eligible shareholders must have bought the stock before 31 March 2026. Payment date: 02 April 2026. Payout ratio is on the higher end at 80%, however this is supported by cash flows. Trailing yield: 4.3%. Within top quartile of Swiss dividend payers (3.6%). Higher than average of industry peers (2.6%). Bekanntmachung • Mar 23
DKSH Holding AG(SWX:DKSH) dropped from FTSE All-World Index (USD) DKSH Holding AG(SWX:DKSH) dropped from FTSE All-World Index (USD) Bekanntmachung • Mar 06
DKSH Holding AG, Annual General Meeting, Mar 27, 2026 DKSH Holding AG, Annual General Meeting, Mar 27, 2026, at 10:00 W. Europe Standard Time. Reported Earnings • Feb 19
Full year 2025 earnings released: EPS: CHF3.12 (vs CHF3.31 in FY 2024) Full year 2025 results: EPS: CHF3.12 (down from CHF3.31 in FY 2024). Revenue: CHF11.1b (flat on FY 2024). Net income: CHF202.9m (down 5.5% from FY 2024). Profit margin: 1.8% (down from 1.9% in FY 2024). Revenue is forecast to grow 3.0% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Bekanntmachung • Feb 18
DKSH Holding AG announces Annual dividend, payable on April 02, 2026 DKSH Holding AG announced Annual dividend of CHF 2.5000 per share payable on April 02, 2026, ex-date on March 31, 2026 and record date on April 01, 2026. Bekanntmachung • Jan 16
DKSH Management AG Announces Retirement of Thomas Sul from the Role as Co-Head and Member of the Executive Committee DKSH Management AG announced that Thomas Sul, Co-Head of the Business Unit Performance Materials and Member of the Executive Committee, has decided to gradually scale down his activities as he eases into retirement and has stepped down from his role as Co-Head and Member of the Executive Committee. Natale Capri, who has served as Co-Head for over ten years, assumes full responsibility as Head of the Business Unit Performance Materials and will remain a Member of the Executive Committee. After nearly 30 years at DKSH, Thomas Sul leaves behind a remarkable legacy. Under his co-leadership, Performance Materials has achieved significant milestones, including driving globalization, strengthening business development, realizing multiple acquisitions, and doubling operating profit. Thomas will continue to contribute his expertise in a strategic capacity after scaling down his activities in the first quarter of 2026. Bekanntmachung • Dec 19
DKSH Holding AG (SWX:DKSH) agreed to acquire Biomedic Science Material Joint Stock Company. DKSH Holding AG (SWX:DKSH) agreed to acquire Biomedic Science Material Joint Stock Company on December 17, 2025.
For the period ending December 31, 2024, Biomedic Science Material Joint Stock Company reported total revenue of CHF 12 million.
The expected completion of the transaction is January 1, 2026 to March 31, 2026. Bekanntmachung • Nov 22
DKSH Management Ltd. Announces Executive Changes DKSH Management Ltd. announced the appointment of Patrik Grande as new Head Business Unit Healthcare as of January 2026. Currently Vice President, Commercial Outsourcing & Cluster Head APAC, he will be a member of DKSH's Executive Committee, report to CEO Stefan P. Butz, and will relocate from Bangkok to Singapore within the next year. Patrik Grande follows Bijay Singh who will begin his retirement on March 31, 2026, after eleven years at DKSH. Patrik Grande is a well-seasoned and accomplished leader with more than 20 years of experience in the global pharmaceutical industry. He joined DKSH in 2022 as Vice President, Business Unit Healthcare Thailand, following a successful two-decade career at Novartis. During his time at Novartis, he held increasingly senior leadership roles across multiple markets, including South Korea, Malaysia, the United Kingdom, Switzerland, Russia, and Spain. Since joining DKSH, Patrik has revitalized the Healthcare business in Thailand and delivered growth. In his role as Vice President, Commercial Outsourcing & Cluster Head APAC, he strengthened the strategic commercial outsourcing pillar, expanded the robust regional capabilities, delivering growth and driving strategic progress across the region. A Spanish citizen, Patrik holds a Master's degree in Business Administration from IESE Business School. Bijay Singh leaves behind an outstanding legacy after eleven years at DKSH, including nearly nine years as Head Business Unit Healthcare and Member of the Executive Committee. Bijay Singh joined DKSH as Vice President, Global Business Development for Business Unit Healthcare in 2015. His tenure was marked by significant achievements such as building robust commercial outsourcing capabilities, driving strategic M&As, expanding the Healthcare business into new markets such as Australia, the Philippines, and South Korea, and fostering a strong talent pipeline. Bekanntmachung • Nov 18
DKSH Reportedly to Weigh Bid for Pharma Distributor Swixx Biopharma DKSH Holding AG (SWX:DKSH) is among the companies exploring a potential acquisition of Swiss pharmaceutical distributor Swixx Biopharma (Swixx Biopharma SA), Bloomberg News reported on November 16, 2025, citing people familiar with the matter. Private-equity firms SK Capital Partners (SK Capital Partners, LP) and Lone Star (Lone Star Americas Acquisitions, Inc.) are also said to be evaluating bids. The sources indicated that Swixx could fetch EUR 1.5 billion to EUR 2 billion ($1.7 billion to $2.2 billion), though talks are ongoing and may not lead to a deal. Additional bidders could still join the process. Swixx, jointly owned by HBM Healthcare Investments and members of its management team, specializes in helping drugmakers navigate distribution in smaller and more regulated markets. The company operates in 44 countries and recorded EUR 900 million in 2023 revenue, according to its website. Zurich-based DKSH, valued at roughly CHF 3.5 billion, runs a similar distribution and marketing platform spanning healthcare, consumer goods, technology and industrial materials. Representatives for DKSH, Lone Star and HBM declined to comment to Bloomberg News. SK Capital did not respond to a request for comment, and Swixx could not be reached. Reported Earnings • Jul 20
First half 2025 earnings: EPS misses analyst expectations First half 2025 results: EPS: CHF1.41 (down from CHF1.71 in 1H 2024). Revenue: CHF5.53b (up 1.5% from 1H 2024). Net income: CHF91.8m (down 17% from 1H 2024). Profit margin: 1.7% (down from 2.0% in 1H 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 9% per year. Bekanntmachung • May 21
DKSH Holding AG (SWX:DKSH) signed an agreement to acquire A.P.N Plastics Pty Ltd. DKSH Holding AG (SWX:DKSH) signed an agreement to acquire A.P.N Plastics Pty Ltd on May 20, 2025. DKSH will acquire the entire business and fully integrate the company into its existing operations. APN Plastics generates annual net sales of more than CHF 25 million. The transaction is subject to customary closing conditions. The closing of the transaction is expected during the second quarter of 2025. Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CHF58.70, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 15x in the Trade Distributors industry in Europe. Total loss to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CHF94.58 per share. Bekanntmachung • Mar 29
DKSH Holding AG Announces Board Changes DKSH Holding AG at its Annual General Meeting held on 27 March 2025, announced Dr. Hans Christoph Tanner did not stand for reelection. Suwannee Ratthayabandith was elected as a new member of the Board of Directors. Upcoming Dividend • Mar 24
Upcoming dividend of CHF2.35 per share Eligible shareholders must have bought the stock before 31 March 2025. Payment date: 02 April 2025. Payout ratio is a comfortable 71% and this is well supported by cash flows. Trailing yield: 3.2%. Lower than top quartile of Swiss dividend payers (4.0%). Higher than average of industry peers (2.4%). Bekanntmachung • Mar 07
DKSH Holding AG to Report First Half, 2025 Results on Jul 17, 2025 DKSH Holding AG announced that they will report first half, 2025 results on Jul 17, 2025 Bekanntmachung • Feb 28
DKSH Holding AG, Annual General Meeting, Mar 27, 2025 DKSH Holding AG, Annual General Meeting, Mar 27, 2025, at 10:00 W. Europe Standard Time. Reported Earnings • Feb 13
Full year 2024 earnings released: EPS: CHF3.31 (vs CHF2.80 in FY 2023) Full year 2024 results: EPS: CHF3.31 (up from CHF2.80 in FY 2023). Revenue: CHF11.1b (flat on FY 2023). Net income: CHF214.8m (up 18% from FY 2023). Profit margin: 1.9% (up from 1.6% in FY 2023). Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 1% per year. Bekanntmachung • Jan 07
DKSH Holding AG (SWX:DKSH) acquired Clmo Technology Sdn. Bhd. DKSH Holding AG (SWX:DKSH) acquired Clmo Technology Sdn. Bhd. on January 7, 2025. Clmo Technology Sdn. Bhd.'s management team will join DKSH Holding AG’s business unit technology.
DKSH Holding AG (SWX:DKSH) completed the acquisition of Clmo Technology Sdn. Bhd. on January 7, 2025. Bekanntmachung • Dec 06
DKSH Holding AG to Report Fiscal Year 2024 Results on Feb 12, 2025 DKSH Holding AG announced that they will report fiscal year 2024 results on Feb 12, 2025 Bekanntmachung • Nov 13
DKSH Healthcare and Euris Unveil CRM & MCE Platform "ConnectPlus" to Revolutionize APAC Healthcare Distribution DKSH Healthcare Business Unit, in partnership with Euris, is introducing ConnectPlus, a data-driven Customer Relationship Management (CRM) and Multi-Channel Engagement (MCE) platform aimed at transforming healthcare distribution across the Asia Pacific region. Designed to enhance productivity and operational efficiency, this platform provides a 360° view of healthcare professionals, streamlines MCE, and strengthens DKSH Healthcare's ability to tailor interactions and marketing strategies. The roll-out will start in Thailand in January 2025. With this new platform DKSH Healthcare reinforces its dedication to commercial excellence by enlarging possibilities and improving interactions with clients, customers, and patients. The introduction of ConnectPlus underscores DKSH Healthcare's commitment to harnessing digital solutions that orchestrate and maximize impact of both client and patient interactions, while upholding a high standard of operational excellence. ConnectPlus empowers DKSH to tap into the vast potential provided by the global healthcare big data market by delivering precise, targeted engagement strategies that cater to the unique needs of healthcare professionals, clients, and patients across the region. Furthermore, ConnectPlus is strategically designed to leverage the existing preference of face-to-face sales visits, by orchestrating personalized digital touchpoints, based on data driven insights, to prepare and enhance in-person interactions. The platform's ability to blend in-person and digital strategies is essential for maximizing outreach and driving meaningful engagement. By integrating advanced AI and analytics, ConnectPlus not only streamlines communication and marketing efforts but also personalizes interactions based on real-time data, ensuring relevance and impact. This marks a crucial milestone in DKSH Healthcare's journey towards fully integrating digital innovation into its operations, reinforcing its leadership in driving agility and efficiency within the rapidly evolving healthcare landscape. Reported Earnings • Jul 18
First half 2024 earnings released: EPS: CHF1.71 (vs CHF1.59 in 1H 2023) First half 2024 results: EPS: CHF1.71 (up from CHF1.59 in 1H 2023). Revenue: CHF5.45b (down 3.3% from 1H 2023). Net income: CHF111.2m (up 7.5% from 1H 2023). Profit margin: 2.0% (up from 1.8% in 1H 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 4% per year. Upcoming Dividend • Mar 21
Upcoming dividend of CHF2.25 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 03 April 2024. Payout ratio is on the higher end at 80%, however this is supported by cash flows. Trailing yield: 3.6%. Lower than top quartile of Swiss dividend payers (4.1%). Higher than average of industry peers (2.2%). Declared Dividend • Feb 29
Dividend increased to CHF2.25 Dividend of CHF2.25 is 4.7% higher than last year. Ex-date: 28th March 2024 Payment date: 3rd April 2024 Dividend yield will be 3.5%, which is higher than the industry average of 2.3%. Sustainability & Growth Dividend is covered by both earnings (80% earnings payout ratio) and cash flows (43% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 30% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Feb 18
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: EPS: CHF2.80 (down from CHF3.10 in FY 2022). Revenue: CHF11.1b (down 2.2% from FY 2022). Net income: CHF182.0m (down 9.5% from FY 2022). Profit margin: 1.6% (down from 1.8% in FY 2022). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.3%. Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 2.8% growth forecast for the Trade Distributors industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has fallen by 2% per year. Price Target Changed • Nov 21
Price target decreased by 7.4% to CHF73.90 Down from CHF79.80, the current price target is an average from 6 analysts. New target price is 31% above last closing price of CHF56.50. Stock is down 22% over the past year. The company is forecast to post earnings per share of CHF3.16 for next year compared to CHF3.09 last year. Bekanntmachung • Sep 19
DKSH Holding AG (SWX:DKSH) agreed to acquire CS Company Ltd. DKSH Holding AG (SWX:DKSH) agreed to acquire CS Company Ltd on September 18, 2023. CS Company generates net sales of over CHF 35 million. The deal is expected to close in the fourth quarter, subject to certain conditions. Reported Earnings • Jul 20
First half 2023 earnings released: EPS: CHF1.59 (vs CHF1.58 in 1H 2022) First half 2023 results: EPS: CHF1.59 (up from CHF1.58 in 1H 2022). Revenue: CHF5.63b (flat on 1H 2022). Net income: CHF103.4m (flat on 1H 2022). Profit margin: 1.8% (in line with 1H 2022). Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 5.4% growth forecast for the Professional Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Buying Opportunity • Jun 22
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 8.1%. The fair value is estimated to be CHF83.15, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 3.6% per annum. Earnings is also forecast to grow by 8.7% per annum over the same time period. Bekanntmachung • May 31
DKSH Holding AG to Report First Half, 2023 Results on Jul 18, 2023 DKSH Holding AG announced that they will report first half, 2023 results on Jul 18, 2023 Buying Opportunity • May 17
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 15%. The fair value is estimated to be CHF84.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 3.6% per annum. Earnings is also forecast to grow by 8.7% per annum over the same time period. Price Target Changed • May 12
Price target decreased by 12% to CHF70.83 Down from CHF80.83, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of CHF69.85. Stock is down 14% over the past year. The company is forecast to post earnings per share of CHF3.34 for next year compared to CHF3.09 last year. Bekanntmachung • May 11
DKSH Appoints Chris Ritchie as New Head Business Unit Consumer Goods DKSH announced the appointment of Chris Ritchie as new Head Business Unit Consumer Goods as of mid-August 2023. Based in Singapore, he will be a member of DKSH's Executive Committee and report to CEO Stefan P. Butz. Chris Ritchie follows Terry Seremetis, who, after four years, decided to pursue his career opportunities outside of DKSH as announced on January 3, 2023. Chris Ritchie has 28 years of experience in the consumer goods industry. For the last four years, he was Chief Global Business Officer of Sazerac, a leading privately held American spirit company, where he oversaw operations in Asia Pacific and Europe. From 2016 to 2019, he was General Manager at Reckitt Benckiser, responsible for the growth market Philippines. Prior to that, from 2007 to 2016, he held various General Manager and Director positions at SABMiller in Asia, Europe, and Americas, including Managing Director of SABMiller Vietnam. From 1995 to 2006, he held regional and global marketing roles at P&G. Throughout his career, Chris has driven growth, route-to-market, and built strong teams, especially in developing markets. A Canadian citizen,Chris (50 years) holds a Bachelor's degree in Economics from Queen's University in Kingston, Canada. Buying Opportunity • Mar 18
Now 21% undervalued Over the last 90 days, the stock is up 3.3%. The fair value is estimated to be CHF92.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 3.9% per annum. Earnings is also forecast to grow by 8.9% per annum over the same time period. Upcoming Dividend • Mar 13
Upcoming dividend of CHF2.15 per share at 2.8% yield Eligible shareholders must have bought the stock before 20 March 2023. Payment date: 22 March 2023. Payout ratio is a comfortable 69% and this is well supported by cash flows. Trailing yield: 2.8%. Lower than top quartile of Swiss dividend payers (4.2%). In line with average of industry peers (2.6%). Buying Opportunity • Mar 01
Now 20% undervalued Over the last 90 days, the stock is up 7.8%. The fair value is estimated to be CHF95.74, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 3.9% per annum. Earnings is also forecast to grow by 8.8% per annum over the same time period. Buying Opportunity • Feb 10
Now 19% undervalued Over the last 90 days, the stock is up 14%. The fair value is estimated to be CHF98.76, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 13%. For the next 3 years, revenue is forecast to grow by 4.1% per annum. Earnings is also forecast to grow by 8.7% per annum over the same time period. Reported Earnings • Feb 10
Full year 2022 earnings released: EPS: CHF3.09 (vs CHF3.45 in FY 2021) Full year 2022 results: EPS: CHF3.09 (down from CHF3.45 in FY 2021). Revenue: CHF11.4b (up 2.1% from FY 2021). Net income: CHF201.1m (down 10% from FY 2021). Profit margin: 1.8% (down from 2.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Professional Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 10% per year. Bekanntmachung • Dec 31
Pascal Raffy agreed to acquire 25% stake in Bovet Fleurier S.A. from DKSH Holding AG (SWX:DKSH). Pascal Raffy agreed to acquire 25% stake in Bovet Fleurier S.A. from DKSH Holding AG (SWX:DKSH) on December 29, 2022. The transaction does not materially affect DKSH's profit and loss statement. Buying Opportunity • Dec 07
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 3.3%. The fair value is estimated to be CHF87.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 7.3%. For the next 3 years, revenue is forecast to grow by 3.4% per annum. Earnings is also forecast to grow by 4.3% per annum over the same time period. Board Change • Nov 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Chairman of the Board Marco Gadola was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Buying Opportunity • Nov 12
Now 24% undervalued after recent price drop Over the last 90 days, the stock is down 8.6%. The fair value is estimated to be CHF92.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 7.3%. Revenue is forecast to grow by 8.5% in 2 years. Earnings is forecast to grow by 2.7% in the next 2 years. Bekanntmachung • Nov 08
DKSH Holding AG (SWX:DKSH) signed an agreement to acquire Two pharma brands of Eisai. DKSH Holding AG (SWX:DKSH) signed an agreement to acquire Two pharma brands of Eisai on November 7, 2022. Bekanntmachung • Nov 01
DKSH Holding AG acquired 80% stake in Terra Firma. DKSH Holding AG agreed to acquire 80% stake in Terra Firma on September 22, 2022. The remainder stake will be held by Terra Firma's existing management team. Frank Gerhard, Jürg Frick and Eduard De Zordi of Homburger AG acted as legal advisor to DKSH Holding AG. BofA Securities acted as financial advisor to DKSH.
DKSH Holding AG completed the acquisition of 80% stake in Terra Firma November 01, 2022. Bekanntmachung • Sep 24
DKSH Holding AG agreed to acquire Terra Firma. DKSH Holding AG agreed to acquire an 80% stake in Terra Firma on September 22, 2022. The remainder stake will be held by Terra Firma's existing management team. Frank Gerhard, Jürg Frick and Eduard De Zordi of Homburger AG acted as legal advisor to DKSH Holding AG. Bekanntmachung • Jul 15
DKSH Provides Earnings Guidance for the Year 2022 DKSH provided earnings guidance for the year 2022. The company expects EBIT growth in 2022. Bekanntmachung • Jun 28
DKSH Holding AG (SWX:DKSH) agreed to acquire Refarmed Chemicals SA. DKSH Holding AG (SWX:DKSH) agreed to acquire Refarmed Chemicals SA on June 27, 2022. DKSH will acquire the business and will fully integrate the company into its existing operations. Frank Gerhard and Reto Heuberger of Homburger AG acted as legal advisor to DKSH Holding AG. Bekanntmachung • Jun 01
DKSH Holding AG (SWX:DKSH), entered into an agreement to acquire Acutest Systems (M) Sdn. Bhd. DKSH Holding AG (SWX:DKSH), entered into an agreement to acquire Acutest Systems (M) Sdn. Bhd., on May 31, 2022. Acutest Systems reported net sales of CHF 3 million in 2021. Acutest employees will join DKSH. The closing of the transaction is expected during the second quarter of 2022 and is subject to certain conditions. Bekanntmachung • May 30
DKSH Holding AG (SWX:DKSH) agreed to acquire DNIV Group. DKSH Holding AG (SWX:DKSH) agreed to acquire DNIV Group on May 30, 2022. DNIV Group has 110 employees and for the year ended 2021, DNIV Group has recorded sales of more than CHF 45 million. Transaction is subject to certain closing conditions and is expected to during the second quarter of 2022 
